Pfizer’s ELREXFIO Outperforms Standard Regimens and Meets Primary Endpoint in Phase 3 Study in Relapsed or Refractory Multiple Myeloma
Pfizer's Phase 3 MagnetisMM-32 trial met its primary endpoint, with ELREXFIO (elranatamab) monotherapy showing a statistically significant and clinically meaningful progression-free survival benefit versus investigator's choice of three standard regimens in relapsed/refractory multiple myeloma after anti-CD38 therapy and lenalidomide. Median PFS was not yet reached, with more than 75% of patients progression-free at analysis and an estimated 68% PFS at 18 months; the safety profile was consistent with the known label with no new safety signals.
Key figures
- Drug Name
- ELREXFIO (elranatamab)
- Phase Of Trial
- Phase 3
- Countries
- 26
- Enrolled patients
- 523
- Estimated pfs 18 months
- 68%
- Grade5 infections control
- 1.6%
- Grade5 infections elrexfio
- 0.8%
- Grade3plus infections control
- 18.1%
- Grade3plus infections elrexfio
- 27.5%
- Patients progression free at analysis
- >75%
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.